PDX Pharma was granted a new U.S. Patent (US12059500) on August 13, 2024, marking the third U.S. patent for our ARAC™ technology! ARAC™ is based on our innovative Pdx-NP™ nanoparticle platform, which co-delivers antigen release agents and immune checkpoint inhibitors to elicit a potent anti-tumor immune response. The key claims in this patent include PD-L1 antibody-conjugated Pdx-NP loaded with “any” cancer therapeutics. This new addition to our patent portfolio not only extends our protection but also strengthens our commitment to advancing the ARAC™ pipeline. We are incredibly proud of this achievement, made possible by our dedicated team members and inventors, Drs. Moataz Reda and Worapol (Boom) Ngamcherdtrakul, along with our OHSU collaborator and PDX Pharma’s CEO, Dr. Wassana Yantasee. Stay tuned for more exciting updates!